array(3) { ["company_details"]=> array(13) { ["name"]=> string(13) "Pharming B.V." ["slug"]=> string(20) "00474-nl-pharming-bv" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776" ["description"]=> string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates." ["address_street"]=> string(12) "Darwinweg 24" ["address_place"]=> string(6) "Leiden" ["address_region"]=> NULL ["founding_date"]=> NULL ["website_domain"]=> string(12) "pharming.com" ["website_url"]=> string(24) "https://www.pharming.com" ["industry_codes"]=> array(1) { [0]=> string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified" } ["employee_count"]=> NULL ["article_count"]=> int(55) } ["articles"]=> array(8) { [0]=> array(7) { ["title_en"]=> string(84) "Pharming's share price rises by more than 9% thanks to higher than expected turnover" ["snippet_en"]=> string(145) "Sales growth of 10% from medicine Ruconest is higher than the company expected. Investors react enthusiastically to the message and set course..." ["url"]=> string(111) "https://fd.nl/financiele-markten/3693272/1502485/koers-pharming-stijgt-ruim-9-dankzij-hoger-dan-verwachte-omzet" ["image_url"]=> NULL ["source"]=> string(5) "fd.nl" ["publication_date"]=> string(10) "2024-01-08" ["categories"]=> array(5) { [0]=> string(25) "Business Model Resilience" [1]=> string(12) "Stock Market" [2]=> string(15) "Market Movement" [3]=> string(24) "Quarterly/Annual Figures" [4]=> string(9) "Investors" } } [1]=> array(7) { ["title_en"]=> string(75) "Pharming Group to report third quarter 2023 financial results on October 26" ["snippet_en"]=> string(276) "Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023." ["url"]=> string(81) "https://finance.yahoo.com/news/pharming-group-report-third-quarter-060000578.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/222fecfb-6b72-4556-9f3b-642d69c24b75" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-10-12" ["categories"]=> array(5) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(12) "Stock Market" [2]=> string(24) "Quarterly/Annual Figures" [3]=> string(18) "Financial Distress" [4]=> string(9) "Investors" } } [2]=> array(7) { ["title_en"]=> string(99) "Pharming is doing well in the US - strong sales from both Ruconest and Joenja in the past half year" ["snippet_en"]=> string(154) "After the approval on 24 March of the new drug Joenja (leniolisib) from the Leiden biotech company Pharming in the US, sales have got off to a good start." ["url"]=> string(52) "https://m.leidschdagblad.nl/cnt/dmf20230803_38222919" ["image_url"]=> string(78) "https://images.businessradar.com/articles/4602cc36-5697-46bb-ac70-22ad24dc4b5b" ["source"]=> string(17) "leidschdagblad.nl" ["publication_date"]=> string(10) "2023-08-03" ["categories"]=> array(3) { [0]=> string(21) "Financial Performance" [1]=> string(18) "China-US Relations" [2]=> string(24) "Quarterly/Annual Figures" } } [3]=> array(7) { ["title_en"]=> string(52) "Attention to quarterly figures ING and SBM at Damrak" ["snippet_en"]=> string(303) "SBM Offshore saw turnover fall by almost a quarter in the first quarter. CEO Bruno Chabas nevertheless spoke of good performance and maintained expectations for the entire year. The company will also pay out 10 percent more dividend over 2022. Pharming also came up with figures. The biotechnologist saw" ["url"]=> string(84) "https://www.rd.nl/artikel/1019815-aandacht-voor-kwartaalcijfers-ing-en-sbm-op-damrak" ["image_url"]=> NULL ["source"]=> string(5) "rd.nl" ["publication_date"]=> string(10) "2023-05-11" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(12) "Stock Market" } } [4]=> array(7) { ["title_en"]=> string(48) "Pharming's cash position grows to $208.7 million" ["snippet_en"]=> string(147) "The cash position of the Leiden pharmaceutical and biotech company Pharming increased to $ 208.7 million last year. The company reported this to..." ["url"]=> string(89) "https://fd.nl/financiele-markten/3693272/1470818/kaspositie-pharming-groeit-tot-208-7-mln" ["image_url"]=> NULL ["source"]=> string(5) "fd.nl" ["publication_date"]=> string(10) "2023-03-16" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(18) "General Investment" } } [5]=> array(7) { ["title_en"]=> string(25) "Preview: Figures and tips" ["snippet_en"]=> string(151) "We discuss the Fed interest rate decision and provide a preview of the half-year figures of KPN, Besi, Fugro, ArcelorMiital and Pharming, among others." ["url"]=> string(75) "https://www.iex.nl/premium/adviezen/504698/vooruitblik-cijfers-en-tips.aspx" ["image_url"]=> NULL ["source"]=> string(6) "iex.nl" ["publication_date"]=> string(10) "2020-07-26" ["categories"]=> array(2) { [0]=> string(7) "Economy" [1]=> string(24) "Quarterly/Annual Figures" } } [6]=> array(7) { ["title_en"]=> string(70) "Pharming Group to report first quarter 2024 financial results on May 8" ["snippet_en"]=> string(304) "Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for" ["url"]=> string(142) "https://kommunikasjon.ntb.no/pressemelding/18070967/pharming-group-to-report-first-quarter-2024-financial-results-on-may-8?publisherId=4954260" ["image_url"]=> string(78) "https://images.businessradar.com/articles/901a2228-20e4-4ae4-824d-d26a8c659580" ["source"]=> string(6) "ntb.no" ["publication_date"]=> NULL ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" } } [7]=> array(7) { ["title_en"]=> string(23) "Pharming records a loss" ["snippet_en"]=> string(239) "(ABM FN-Dow Jones) Pharming Group plunged into the red in the first quarter. This emerged from figures from the biotech company on Thursday. In the past quarter of 2023, Pharming reached an important milestone with the approval and long..." ["url"]=> string(69) "https://www.beursgorilla.nl/Nieuws/772880/Pharming-boekt-verlies.aspx" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c8fc19ea-3461-4524-8660-9ad071e21e6e" ["source"]=> string(15) "beursgorilla.nl" ["publication_date"]=> NULL ["categories"]=> array(4) { [0]=> string(21) "Financial Performance" [1]=> string(24) "Quarterly/Annual Figures" [2]=> string(31) "Financial Update/Profit Warning" [3]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(28) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(13) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(8) } [2]=> array(2) { ["name"]=> string(10) "Insolvency" ["count"]=> int(4) } [3]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(4) } [4]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(3) } [5]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(3) } [6]=> array(2) { ["name"]=> string(21) "Financial Performance" ["count"]=> int(2) } [7]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(2) } [8]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(2) } [9]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [10]=> array(2) { ["name"]=> string(10) "Executives" ["count"]=> int(1) } [11]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(1) } [12]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(1) } [13]=> array(2) { ["name"]=> string(24) "Government Interventions" ["count"]=> int(1) } [14]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(1) } [15]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(1) } [22]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(1) } [23]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(1) } [24]=> array(2) { ["name"]=> string(5) "Debts" ["count"]=> int(1) } [25]=> array(2) { ["name"]=> string(19) "Economic Conditions" ["count"]=> int(1) } [26]=> array(2) { ["name"]=> string(7) "Economy" ["count"]=> int(1) } [27]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(1) } } } 00474-nl-pharming-bv